1. Home
  2. BXSL vs RGEN Comparison

BXSL vs RGEN Comparison

Compare BXSL & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Secured Lending Fund of Beneficial Interest

BXSL

Blackstone Secured Lending Fund of Beneficial Interest

HOLD

Current Price

$27.34

Market Cap

6.4B

Sector

Finance

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$162.24

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXSL
RGEN
Founded
2018
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
8.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BXSL
RGEN
Price
$27.34
$162.24
Analyst Decision
Buy
Buy
Analyst Count
8
10
Target Price
$29.38
$174.90
AVG Volume (30 Days)
1.5M
681.2K
Earning Date
11-10-2025
10-28-2025
Dividend Yield
11.20%
N/A
EPS Growth
N/A
N/A
EPS
2.66
0.03
Revenue
$1,413,784,000.00
$707,890,000.00
Revenue This Year
$9.05
$17.84
Revenue Next Year
$0.28
$12.57
P/E Ratio
$10.35
$6,198.22
Revenue Growth
10.58
11.74
52 Week Low
$24.85
$102.97
52 Week High
$34.64
$182.52

Technical Indicators

Market Signals
Indicator
BXSL
RGEN
Relative Strength Index (RSI) 44.93 53.78
Support Level $28.03 $156.01
Resistance Level $28.59 $165.02
Average True Range (ATR) 0.43 4.65
MACD -0.11 -1.09
Stochastic Oscillator 7.14 41.21

Price Performance

Historical Comparison
BXSL
RGEN

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: